Avid Bioservices Inc (CDMO)

[BioBS2012]

I doubt this study will provide anything more than something of scientific curiosity. Assuming animal models to some extent predict human performance, if you look at this poster from 2015 SITC, you will see that the PS targeting antibody (mch1N11) performed much better when combined with an anti-PD-1 than an anti-CTLA-4. Of course at the time they conceived the study CTLA-4 (Ipilimumab) was the drug of choice for melanoma.

http://www.peregrineinc.com/images/stories/pdfs/sitc_2015_melanoma_huang.pdf